These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710 [TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442 [TBL] [Abstract][Full Text] [Related]
8. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression. Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP; J Neurol; 2024 Aug; 271(8):5074-5082. PubMed ID: 38805052 [TBL] [Abstract][Full Text] [Related]
9. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659 [TBL] [Abstract][Full Text] [Related]
11. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367 [TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate. Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162 [TBL] [Abstract][Full Text] [Related]
13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Cree BAC; Pradhan A; Pei J; Williams MJ; Mult Scler Relat Disord; 2021 Jul; 52():103010. PubMed ID: 34147885 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567 [TBL] [Abstract][Full Text] [Related]
16. How patients with multiple sclerosis acquire disability. Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840 [TBL] [Abstract][Full Text] [Related]